Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib

Blood

Volumn 128, Issue 15, 2016, Pages 1940-1943

  Ahn, Inhye E ^a   Jerussi, Theresa ^b   Farooqui, Mohammed ^c   Tian, Xin ^d   Wiestner, Adrian ^c   Gea Banacloche, Juan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; BRUTON TYROSINE KINASE; COTRIMOXAZOLE; IBRUTINIB; IMMUNOGLOBULIN G; LEVOFLOXACIN; TOBRAMYCIN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC COUGH; CHRONIC LYMPHATIC LEUKEMIA; DELAYED DIAGNOSIS; DIRECT FLUORESCENCE ANTIBODY STAINING; DRUG SUBSTITUTION; DYSPNEA; ENZYME INHIBITION; FOLLOW UP; FUNGUS IDENTIFICATION; HUMAN; HUMAN CELL; INCIDENCE; INFECTION PREVENTION; INFECTION SENSITIVITY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LUNG INFILTRATE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; STAINING; TIME TO TREATMENT; TREATMENT DURATION; CASE REPORT; CHEMICALLY INDUCED; CLINICAL TRIAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS;

AGED; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PYRAZOLES; PYRIMIDINES;

EID: 84991735336     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-06-722991     Document Type: Article

References (19)

1. Byrd JC, Brown JR, O'Brien S, et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
2. Burger JA, Tedeschi A, Barr PM, et al; RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437.
3. Eichhorst B, Fink AM, Bahlo J, et al; International Group of Investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928-942.
4. Hallek M, Fischer K, Fingerle-Rowson G, et al; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
5. Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169-176.
6. Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219.
7. Kalkanis A, Judson MA, Napier MB. Pneumocystis jerovecii pneumonia in a patient with untreated chronic lymphocytic leukaemia: a novel case and postulations concerning the mechanism. BMJ Case Rep. November 28, 2013. doi:10.1136/bcr-2013-202124.
8. Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145-153.
9. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993;82(6):1695-1700.
10. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209-3216.
11. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
12. Bienvenu AL, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis. 2016;46:11-17.
13. Reid AB, Chen SC, Worth LJ. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis. 2011;24(6):534-544.
14. Azoulay E, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest. 2009;135(3):655-661.
15. Hashimoto K, Kobayashi Y, Asakura Y, et al. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma. 2010;51(10):1816-1821.
16. Kanegane H, Nakano T, Shimono Y, Zhao M, Miyawaki T. Pneumocystis jiroveci pneumonia as an atypical presentation of X-linked agammaglobulinemia. Int J Hematol. 2009;89(5):716-717.
17. Martin-Garrido I, Carmona EM, Specks U, Limper AH. Pneumocystis pneumonia in patients treated with rituximab. Chest. 2013;144(1):258-265.
18. Al-Saud BK, Al-Sum Z, Alassiri H, et al. Clinical, immunological, and molecular characterization of hyper-IgM syndrome due to CD40 deficiency in eleven patients. J Clin Immunol. 2013;33(8):1325-1335.
19. Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011;13(4):R115.